Reuters logo
BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects
August 28, 2017 / 12:46 PM / 4 months ago

BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects

Aug 28 (Reuters) - Coherus Biosciences Inc

* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects

* Coherus Biosciences Inc - ‍Study met criteria for clinical PK/BE on all prospectively defined endpoints​

* Coherus Biosciences - ‍Both agents well tolerated, there were no clinical meaningful differential adverse events observed between two agents in study​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below